Quarterly report pursuant to Section 13 or 15(d)

Collaboration and License Agreements and Supply Agreements - Summary of Recognized Revenue (Details)

v3.20.2
Collaboration and License Agreements and Supply Agreements - Summary of Recognized Revenue (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Revenue Recognition Multiple Deliverable Arrangements [Line Items]        
Total revenue [1] $ 17,823 $ 12,277 $ 34,444 $ 31,431
Collaboration and License Agreements and Supply Agreements        
Revenue Recognition Multiple Deliverable Arrangements [Line Items]        
Total revenue 17,823 12,277 34,444 31,431
Collaboration and License Agreements and Supply Agreements | Bristol-Myers Squibb Company ("BMS")        
Revenue Recognition Multiple Deliverable Arrangements [Line Items]        
Total revenue 7,119 3,354 10,673 6,599
Collaboration and License Agreements and Supply Agreements | Merck        
Revenue Recognition Multiple Deliverable Arrangements [Line Items]        
Total revenue 9,055 5,488 18,837 15,620
Collaboration and License Agreements and Supply Agreements | Vaxcyte, Inc.        
Revenue Recognition Multiple Deliverable Arrangements [Line Items]        
Total revenue 142 786 278 1,067
Collaboration and License Agreements and Supply Agreements | Merck KGaA, Darmstadt, Germany "EMD Serono")        
Revenue Recognition Multiple Deliverable Arrangements [Line Items]        
Total revenue $ 1,507 $ 2,649 $ 4,656 $ 8,145
[1] Includes $0 and $2.8 million, respectively, for the three months and nine months ended September 30, 2020 of related party revenue from Merck. Merck was a related party until the closing of the Company’s public offering on May 14, 2020.